Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.

Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM.

Cancer. 2014 Feb 1;120(3):344-51. doi: 10.1002/cncr.28421. Epub 2013 Oct 24.

2.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

3.

Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.

Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL.

Gynecol Oncol. 2013 Feb;128(2):155-9. doi: 10.1016/j.ygyno.2012.11.034. Epub 2012 Nov 29.

4.

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM.

Gynecol Oncol. 2012 Dec;127(3):456-61. doi: 10.1016/j.ygyno.2012.08.030. Epub 2012 Sep 7.

PMID:
22960004
5.

Social influences on clinical outcomes of patients with ovarian cancer.

Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Zimmerman MB, Penedo FJ, Lucci JA 3rd, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole SW, Sood AK.

J Clin Oncol. 2012 Aug 10;30(23):2885-90. doi: 10.1200/JCO.2011.39.4411. Epub 2012 Jul 16.

6.

Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.

Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL.

J Clin Oncol. 2012 Nov 1;30(31):3786-91. doi: 10.1200/JCO.2011.41.2528. Epub 2012 Jul 2.

7.

Endometrial cancer.

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, Yang S.

Obstet Gynecol Clin North Am. 2012 Jun;39(2):255-68. doi: 10.1016/j.ogc.2012.04.001.

8.

Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial.

Engle DB, Connor JP, Morris PC, Bender DP, De Geest K, Ahmed A, Goodheart MJ.

Arch Gynecol Obstet. 2012 Sep;286(3):717-21. doi: 10.1007/s00404-012-2351-1. Epub 2012 May 9.

PMID:
22569711
9.

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB.

Gynecol Oncol. 2012 Jun;125(3):635-9. doi: 10.1016/j.ygyno.2012.03.023. Epub 2012 Mar 22.

10.

Endometrial cancer: reviving progesterone therapy in the molecular age.

Yang S, Thiel KW, De Geest K, Leslie KK.

Discov Med. 2011 Sep;12(64):205-12. Review.

11.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.

Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.

12.

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.

Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL.

Gynecol Oncol. 2011 Mar;120(3):459-63. doi: 10.1016/j.ygyno.2010.11.012. Epub 2010 Dec 7.

PMID:
21144560
13.

Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.

Cella D, Huang H, Homesley HD, Montag A, Salani R, De Geest K, Lee R, Spirtos NM.

Gynecol Oncol. 2010 Dec;119(3):538-42. doi: 10.1016/j.ygyno.2010.08.022. Epub 2010 Sep 21.

PMID:
20863554
14.

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A.

Gynecol Oncol. 2010 Jun;117(3):440-5. doi: 10.1016/j.ygyno.2010.02.005. Epub 2010 Mar 24.

15.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE.

J Clin Oncol. 2010 Jan 1;28(1):149-53. doi: 10.1200/JCO.2009.24.1455. Epub 2009 Nov 16.

16.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM.

J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305.

17.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK.

Clin Cancer Res. 2008 Jun 1;14(11):3372-9. doi: 10.1158/1078-0432.CCR-07-4433.

18.

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK.

J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. doi: 10.1093/jnci/djn024. Epub 2008 Feb 26.

19.

Metastatic choriocarcinoma to the lung coexistent with a viable pregnancy.

Ahmed A, De Geest K, Van Natta T, Sorosky J.

Int J Gynaecol Obstet. 2006 Jul;94(1):56-7. Epub 2006 Jun 8. No abstract available.

PMID:
16762354
20.

Epigenetic regulation of maspin expression in human ovarian carcinoma cells.

Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De Geest K, Domann FE.

Gynecol Oncol. 2006 Aug;102(2):319-24. Epub 2006 Feb 7.

PMID:
16457875
21.

Social support, psychological distress, and natural killer cell activity in ovarian cancer.

Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM.

J Clin Oncol. 2005 Oct 1;23(28):7105-13.

PMID:
16192594
22.

Adenosarcoma in a patient with vaginal endometriosis.

Anderson J, Behbakht K, De Geest K, Bitterman P.

Obstet Gynecol. 2001 Nov;98(5 Pt 2):964-6.

PMID:
11704223
23.

Multimodality therapy for carcinoma of the Bartholin gland.

Massad LS, De Geest K.

Gynecol Oncol. 1999 Nov;75(2):305-7.

PMID:
10525393
24.

Smoking, obesity, and survival in squamous cell carcinoma of the vulva.

Kirschner CV, Yordan EL, De Geest K, Wilbanks GD.

Gynecol Oncol. 1995 Jan;56(1):79-84.

PMID:
7821852
25.

Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-beta 1.

De Geest K, Bergman CA, Turyk ME, Frank BS, Wilbanks GD.

Gynecol Oncol. 1994 Dec;55(3 Pt 1):376-85.

PMID:
7835777
26.

Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.

Massad LS, Wagley E, Winkelman L, Lincoln S, Yordan EL, de Geest K, Wilbanks GD.

Eur J Gynaecol Oncol. 1994;15(5):337-42.

PMID:
7828601
27.

Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines.

De Geest K, Turyk ME, Hosken MI, Hudson JB, Laimins LA, Wilbanks GD.

Gynecol Oncol. 1993 Jun;49(3):303-10.

PMID:
8390960
28.

Scalene lymph node biopsy in the preoperative evaluation of patients with recurrent cervical cancer.

Manetta A, Podczaski ES, Larson JE, De Geest K, Mortel R.

Gynecol Oncol. 1989 Jun;33(3):332-4.

PMID:
2722059
29.

Plasma oxytocin in human pregnancy and parturition.

de Geest K, Thiery M, Piron-Possuyt G, Vanden Driessche R.

J Perinat Med. 1985;13(1):3-13. Review.

PMID:
3891956
30.

Endocervical prostaglandin E2 gel for preinduction cervical softening.

Thiery M, Decoster JM, Parewijck W, Noah ML, Derom R, Van Kets H, Defoort P, Aertsens W, Debruyne G, De Geest K, et al.

Prostaglandins. 1984 Mar;27(3):429-39.

PMID:
6374766

Supplemental Content

Loading ...
Support Center